Table 2.
Within-trial analysis: base-case and scenario analysis results
| Total (SD) | Incremental (95% CI) | ICER (£) | |||
|---|---|---|---|---|---|
| Costs (£) | QALYs | Costs (£) | QALYsa | ||
| Base-case analysis | |||||
| Bevacizumab | 6292 (5759–6824) | 1.666 (1.629–1.704) | – | – | |
| Ranibizumab | 13,014 (12,444–13,584) | 1.627 (1.588–1.666) | 6734 (5970–7498) | − 0.019 (− 0.066 to 0.028) | Dominated |
| Aflibercept | 14,328 (13,731–14,925) | 1.651 (1.613–1.690) | 7984 (7209–8759) | − 0.015 (− 0.062 to 0.032) | Dominated |
| Scenario analysis: EQ-5D for utilities | |||||
| Bevacizumab | 6273 (5738–6808) | 1.535 (1.476–1.595) | – | – | |
| Ranibizumab | 13,068 (12,493–13,643) | 1.513 (1.454–1.572) | 6769 (5987–7550) | − 0.010 (− 0.071 to 0.050) | Dominated |
| Aflibercept | 14,271 (13,661–14,882) | 1.560 (1.499–1.619) | 8035 (7246–8824) | 0.008 (− 0.053 to 0.068) | 1,041,476 |
| Scenario analysis: EQ-5D V for utilities | |||||
| Bevacizumab | 6268 (5736–6800) | 1.500 (1.441–1.5591) | – | – | |
| Ranibizumab | 13,000 (12,421–13,579) | 1.472 (1.414–1.530) | 6748 (5948–7547) | − 0.035 (− 0.117 to 0.048) | Dominated |
| Aflibercept | 14,273 (13,684–14,861) | 1.516 (1.455–1.577) | 8012 (7232–8793) | 0.003 (− 0.084 to 0.090) | 2,483,943 |
| Complete case analysis | |||||
| Bevacizumab | 6459 (5587–7332) | 1.651 (1.603–1.699) | |||
| Ranibizumab | 12,608 (11,756–13,461) | 1.656 (1.609–1.703) | 6149 (4929–7369) | 0.007 (− 0.046 to 0.060) | 890,736 |
| Aflibercept | 14,013 (13,167–14,859) | 1.691 (1.644–1.737) | 1405 (204–2606) | 0.011 (− 0.041 to 0.063) | 130,020 |
| Scenario analysis: 52 weeks | |||||
| Bevacizumab | 3621 (3302–3940) | 0.884 (0.866–0.903) | – | – | |
| Ranibizumab | 8164 (7822–8506) | 0.865 (0.845–0.884) | 4565 (4085–5045) | − 0.008 (− 0.030 to 0.014) | Dominated |
| Aflibercept | 9214 (8860–9568) | 0.880 (0.861–0.899) | 5560 (5082–6039) | − 0.004 (− 0.026 to 0.017) | Dominated |
| Scenario analysis: bevacizumab list price from BNF (£243) | |||||
| Bevacizumab | 8933 (8384–9482) | 1.666 (1.629–1.704) | – | – | |
| Ranibizumab | 13,014 (12,433–13,595) | 1.627 (1.588–1.666) | 4093 (3281–4904) | −0.019 (− 0.066 to 0.028) | Dominated |
| Aflibercept | 14,328 (13,721–14,935) | 1.651 (1.613–1.690) | 5342 (4552–6133) | − 0.015 (− 0.062 to 0.032) | Dominated |
BNF British National Formulary, CI confidence interval, EQ-5D EuroQol-5 Dimension, EQ-5D V EuroQol-5 Dimension with Vision bolt-on, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SD standard deviation
aAdjusted for baseline utility score